Literature DB >> 30928973

Tollip Inhibits ST2 Signaling in Airway Epithelial Cells Exposed to Type 2 Cytokines and Rhinovirus.

Azzeddine Dakhama1, Reem Al Mubarak1, Nicole Pavelka1, Dennis Voelker1, Max Seibold2, Julie G Ledford3, Monica Kraft3, Liwu Li4, Hong Wei Chu5.   

Abstract

The negative immune regulator Tollip inhibits the proinflammatory response to rhinovirus (RV) infection, a contributor to airway neutrophilic inflammation and asthma exacerbations, but the underlying molecular mechanisms are poorly understood. Tollip may inhibit IRAK1, a signaling molecule downstream of ST2, the receptor of IL-33. This study was carried out to determine whether Tollip downregulates ST2 signaling via inhibition of IRAK1, but promotes soluble ST2 (sST2) production, thereby limiting excessive IL-8 production in human airway epithelial cells during RV infection in a type 2 cytokine milieu (e.g., IL-13 and IL-33 stimulation). Tollip- and IRAK1-deficient primary human tracheobronchial epithelial (HTBE) cells and Tollip knockout (KO) HTBE cells were generated using the shRNA knockdown and CRISPR/Cas9 approaches, respectively. Cells were stimulated with IL-13, IL-33, and/or RV16. sST2, activated IRAK1, and IL-8 were measured. A Tollip KO mouse model was utilized to test if Tollip regulates the airway inflammatory response to RV infection in vivo under IL-13 and IL-33 treatment. Following IL-13, IL-33, and RV treatment, Tollip-deficient (vs. -sufficient) HTBE cells produced excessive IL-8, accompanied by decreased sST2 production but increased IRAK1 activation. IL-8 production following IL-13/IL-33/RV exposure was markedly attenuated in IRAK1-deficient HTBE cells, as well as in Tollip KO HTBE cells treated with an IRAK1 inhibitor or a recombinant sST2 protein. Tollip KO (vs. wild-type) mice developed exaggerated airway neutrophilic responses to RV in the context of IL-13 and IL-33 treatment. Collectively, these data demonstrate that Tollip restricts excessive IL-8 production in type 2 cytokine-exposed human airways during RV infection by promoting sST2 production and inhibiting IRAK1 activation. sST2 and IRAK1 may be therapeutic targets for attenuating excessive neutrophilic airway inflammation in asthma, especially during RV infection.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Airway epithelial cells; Interleukin-8; Rhinovirus; ST2; Tollip; Type 2 cytokines

Mesh:

Substances:

Year:  2019        PMID: 30928973      PMCID: PMC6959119          DOI: 10.1159/000497072

Source DB:  PubMed          Journal:  J Innate Immun        ISSN: 1662-811X            Impact factor:   7.349


  38 in total

1.  The role of rhinovirus in asthma exacerbations.

Authors:  Samuel L Friedlander; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2005-08       Impact factor: 10.793

2.  Negative regulation of toll-like receptor-mediated signaling by Tollip.

Authors:  Guolong Zhang; Sankar Ghosh
Journal:  J Biol Chem       Date:  2001-12-18       Impact factor: 5.157

3.  IL-13 dampens human airway epithelial innate immunity through induction of IL-1 receptor-associated kinase M.

Authors:  Qun Wu; Di Jiang; Sean Smith; Jyoti Thaikoottathil; Richard J Martin; Russell P Bowler; Hong Wei Chu
Journal:  J Allergy Clin Immunol       Date:  2011-12-09       Impact factor: 10.793

Review 4.  IL-33: biological properties, functions, and roles in airway disease.

Authors:  Li Yin Drake; Hirohito Kita
Journal:  Immunol Rev       Date:  2017-07       Impact factor: 12.988

Review 5.  IRAK1: a critical signaling mediator of innate immunity.

Authors:  Sridevi Gottipati; Navin L Rao; Wai-Ping Fung-Leung
Journal:  Cell Signal       Date:  2007-08-23       Impact factor: 4.315

6.  Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation.

Authors:  Hiroko Hayakawa; Morisada Hayakawa; Akihiro Kume; Shin-ichi Tominaga
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

7.  Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

Authors:  Garrett W Rhyasen; Lyndsey Bolanos; Jing Fang; Andres Jerez; Mark Wunderlich; Carmela Rigolino; Lesley Mathews; Marc Ferrer; Noel Southall; Rajarshi Guha; Jonathan Keller; Craig Thomas; Levi J Beverly; Agostino Cortelezzi; Esther N Oliva; Maria Cuzzola; Jaroslaw P Maciejewski; James C Mulloy; Daniel T Starczynowski
Journal:  Cancer Cell       Date:  2013-07-08       Impact factor: 31.743

8.  Tollip SNP rs5743899 modulates human airway epithelial responses to rhinovirus infection.

Authors:  C Huang; D Jiang; D Francisco; R Berman; Q Wu; J G Ledford; C M Moore; Y Ito; C Stevenson; D Munson; L Li; M Kraft; H W Chu
Journal:  Clin Exp Allergy       Date:  2016-09-21       Impact factor: 5.018

9.  A large-scale, consortium-based genomewide association study of asthma.

Authors:  Miriam F Moffatt; Ivo G Gut; Florence Demenais; David P Strachan; Emmanuelle Bouzigon; Simon Heath; Erika von Mutius; Martin Farrall; Mark Lathrop; William O C M Cookson
Journal:  N Engl J Med       Date:  2010-09-23       Impact factor: 91.245

10.  STAT3 and ERK pathways are involved in cell growth stimulation of the ST2/IL1RL1 promoter.

Authors:  Kenji Tago; Satoshi Ohta; Megumi Funakoshi-Tago; Chihiro Aoki-Ohmura; Jitsuhiro Matsugi; Shin-Ichi Tominaga; Ken Yanagisawa
Journal:  FEBS Open Bio       Date:  2017-01-19       Impact factor: 2.693

View more
  9 in total

1.  Year-Long Rhinovirus Infection is Influenced by Atmospheric Conditions, Outdoor Air Virus Presence, and Immune System-Related Genetic Polymorphisms.

Authors:  Ana Filipa Rodrigues; Ana Mafalda Santos; Ana Maria Ferreira; Roberta Marino; Maria Esmeralda Barreira; José Manuel Cabeda
Journal:  Food Environ Virol       Date:  2019-07-26       Impact factor: 2.778

2.  TOLLIP Optimizes Dendritic Cell Maturation to Lipopolysaccharide and Mycobacterium tuberculosis.

Authors:  Sambasivan Venkatasubramanian; Robyn Pryor; Courtney Plumlee; Sarah B Cohen; Jason D Simmons; Alexander J Warr; Andrew D Graustein; Aparajita Saha; Thomas R Hawn; Kevin B Urdahl; Javeed A Shah
Journal:  J Immunol       Date:  2022-07-08       Impact factor: 5.426

Review 3.  Rhinovirus and Innate Immune Function of Airway Epithelium.

Authors:  Haleh Ganjian; Charu Rajput; Manal Elzoheiry; Umadevi Sajjan
Journal:  Front Cell Infect Microbiol       Date:  2020-06-19       Impact factor: 5.293

4.  Innate Immunity of the Lung.

Authors:  Catherine M Greene; Pieter S Hiemstra
Journal:  J Innate Immun       Date:  2019-12-04       Impact factor: 7.349

Review 5.  Toll-Interacting Protein in Pulmonary Diseases. Abiding by the Goldilocks Principle.

Authors:  Xiaoyun Li; Gillian C Goobie; Alyssa D Gregory; Daniel J Kass; Yingze Zhang
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

6.  Tollip interaction with STAT3: a novel mechanism to regulate human airway epithelial responses to type 2 cytokines.

Authors:  Niccolette Schaunaman; Kris Genelyn Dimasuay; Monica Kraft; Hong Wei Chu
Journal:  Respir Res       Date:  2022-02-16

7.  PHLDA1 Suppresses TLR4-Triggered Proinflammatory Cytokine Production by Interaction With Tollip.

Authors:  Hui Peng; Juping Wang; Xuhong Song; Jiangni Huang; Haoming Hua; Fanlu Wang; Ziyun Xu; Jing Ma; Jie Gao; Jing Zhao; Anna Nong; Dongyang Huang; Bin Liang
Journal:  Front Immunol       Date:  2022-02-14       Impact factor: 7.561

8.  Once Upon a Time.

Authors:  Heiko Herwald; Arne Egesten
Journal:  J Innate Immun       Date:  2021-06-09       Impact factor: 7.349

Review 9.  Toll-interacting protein impacts on inflammation, autophagy, and vacuole trafficking in human disease.

Authors:  Xiaoyun Li; Gillian C Goobie; Yingze Zhang
Journal:  J Mol Med (Berl)       Date:  2020-10-31       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.